Product Information

Registration Status: Active

TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML is approved to be sold in Singapore with effective from 2019-04-24. It is marketed by CELLTRION HEALTHCARE SINGAPORE PTE LTD, with the registration number of SIN15671P.

This product contains Rituximab 500mg/50mL in the form of INFUSION, SOLUTION CONCENTRATE. It is approved for use.

This product is manufactured by CELLTRION in KOREA, and Inc. (Plant II) in REPUBLIC OF.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids


For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Mechanism of Action

The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.


* 0.34 L/day [RA patients]

Active Ingredient/Synonyms

AntiCD20 | Rituximab |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank